Atara Biotherap (ATRA) Stock Price, Quote & News

Company Profile

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Ket...

Industry: Biotechnology

Sector: Healthcare

Phone: 805 623 4211

Website: www.atarabio.com

Address:

1280 Rancho Conejo Blvd, Thousand Oaks, United States

Justrise07 Jan. 20 at 3:08 PM

$ATRA company didn’t close shorts !!! Cover or chase ! lol !! Way oversold. $CRMD !!! Let’s go 2x ! Welcome $CRVS member who all booked profit & joined us !!! Let’s go

0 · Reply

TezBunny Jan. 20 at 12:36 PM

$ATRA Let’s cut this sucker down

0 · Reply

TezBunny Jan. 20 at 12:27 PM

$ATRA Let’s get this sucker under $4

0 · Reply

eloweshadow Jan. 19 at 3:50 AM

$ATRA

0 · Reply

StockOrTwist Jan. 18 at 6:29 PM

$ATRA https://www.youtube.com/watch?v=RecXrepRcTc&list=PLG-rFJE9CyVVwaGfeaM4aC1Sg1pegeEeQ&index=16&pp=iAQB0gcJCU8KAYcqIYzv

0 · Reply

PaulLaurent Jan. 17 at 3:28 PM

📉🔻 Top Losers 🔻📉 Last Week $THH $MTEN $SGN $ATRA $MTVA

1 · Reply

Paper_Route_Frank Jan. 17 at 1:24 PM

$ATRA avg 7.30 light position

1 · Reply

jakewelds20 Jan. 16 at 4:11 PM

$ATRA the trump is starting a fight to try and lower drug costs, ill just be an owner here and wait until he announces he won and got his big great drug bill passed, i dont see it happening

0 · Reply

Bran0723 Jan. 16 at 3:23 PM

$ATRA 🔥

0 · Reply

Cadwacker64 Jan. 16 at 2:16 PM

$ATRA so much to make up

0 · Reply

Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel)

Nov 12, 2025, 9:00 AM EST - 2 months ago

Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress

Nov 3, 2025, 9:00 AM EST - 3 months ago

Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Sep 29, 2025, 7:11 AM EDT - 4 months ago

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

ARWR ASMB CORT

Sep 3, 2025, 6:00 PM EDT - 5 months ago

Atara Biotherapeutics Announces Changes to Its Board of Directors

Aug 11, 2025, 4:01 PM EDT - 6 months ago

Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

Jul 24, 2025, 8:57 AM EDT - 6 months ago

Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Jul 24, 2025, 8:00 AM EDT - 6 months ago

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Jul 15, 2025, 8:00 AM EDT - 7 months ago

Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.

Jul 14, 2025, 8:00 AM EDT - 7 months ago

Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)

May 16, 2025, 8:50 PM EDT - 9 months ago

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

May 15, 2025, 8:35 AM EDT - 9 months ago

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

May 15, 2025, 8:30 AM EDT - 9 months ago

Atara Biotherapeutics Announces Pricing of $16 Million Offering

May 5, 2025, 5:06 PM EDT - 9 months ago

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)

Mar 7, 2025, 4:01 PM EST - 11 months ago

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

Mar 1, 2025, 11:00 AM EST - 11 months ago

The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

Feb 15, 2025, 11:00 AM EST - 1 year ago

The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

Feb 14, 2025, 8:11 AM EST - 1 year ago

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws

Feb 11, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation

Feb 10, 2025, 7:00 AM EST - 1 year ago

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Feb 9, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation

Feb 7, 2025, 4:01 PM EST - 1 year ago

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 7, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect

Feb 6, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect

Feb 5, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation

Feb 4, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation

Feb 3, 2025, 11:00 AM EST - 1 year ago

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Atara Biotherapeutics, Inc. For Securities Fraud

Feb 3, 2025, 7:00 AM EST - 1 year ago

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Jan 31, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation

Jan 30, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation

Jan 29, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out

Jan 28, 2025, 11:00 AM EST - 1 year ago

The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into Atara Biotherapeutics, Inc. For Securities Fraud

Jan 28, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out

Jan 28, 2025, 3:23 AM EST - 1 year ago

ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Jan 27, 2025, 8:30 PM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect

Jan 21, 2025, 1:11 PM EST - 1 year ago

FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs

Jan 21, 2025, 7:30 AM EST - 1 year ago

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219

Justrise07 Jan. 20 at 3:08 PM

$ATRA company didn’t close shorts !!! Cover or chase ! lol !! Way oversold. $CRMD !!! Let’s go 2x ! Welcome $CRVS member who all booked profit & joined us !!! Let’s go

0 · Reply

TezBunny Jan. 20 at 12:36 PM

$ATRA Let’s cut this sucker down

0 · Reply

TezBunny Jan. 20 at 12:27 PM

$ATRA Let’s get this sucker under $4

0 · Reply

eloweshadow Jan. 19 at 3:50 AM

$ATRA

0 · Reply

StockOrTwist Jan. 18 at 6:29 PM

$ATRA https://www.youtube.com/watch?v=RecXrepRcTc&list=PLG-rFJE9CyVVwaGfeaM4aC1Sg1pegeEeQ&index=16&pp=iAQB0gcJCU8KAYcqIYzv

0 · Reply

PaulLaurent Jan. 17 at 3:28 PM

📉🔻 Top Losers 🔻📉 Last Week $THH $MTEN $SGN $ATRA $MTVA

1 · Reply

Paper_Route_Frank Jan. 17 at 1:24 PM

$ATRA avg 7.30 light position

1 · Reply

jakewelds20 Jan. 16 at 4:11 PM

$ATRA the trump is starting a fight to try and lower drug costs, ill just be an owner here and wait until he announces he won and got his big great drug bill passed, i dont see it happening

0 · Reply

Bran0723 Jan. 16 at 3:23 PM

$ATRA 🔥

0 · Reply

Cadwacker64 Jan. 16 at 2:16 PM

$ATRA so much to make up

0 · Reply

SuperGreenToday Jan. 16 at 11:30 AM

$ATRA

0 · Reply

Bildur79 Jan. 16 at 3:04 AM

$ATRA after hours is decent. With some volume and chatter she might spike.

0 · Reply

jeffthechef Jan. 15 at 8:53 PM

@ACInvestorBlog $ATRA nice action and volume! Ah runner. imo

0 · Reply

LF5 Jan. 15 at 5:37 PM

$ATRA Making some nice progress today. It still has plenty more in the tank IMO. We just need more buyer volume today. I’ll be watching it closely during PH.

0 · Reply

StockOrTwist Jan. 15 at 5:03 PM

$ATRA https://www.youtube.com/watch?v=RecXrepRcTc&list=PLG-rFJE9CyVVwaGfeaM4aC1Sg1pegeEeQ&index=11&pp=iAQBhttps://www.youtube.com/watch?v=RecXrepRcTc&list=PLG-rFJE9CyVVwaGfeaM4aC1Sg1pegeEeQ&index=11&pp=iAQB

0 · Reply

ninergizer Jan. 14 at 11:47 PM

$ARWR $MIST $INVA First five on my list was approved $ATRA had CRL, waiting game until buy out or a meeting with FDA as this was already approved in EU. I have my next top 10 PDUFA coming soon.

1 · Reply

drbrain00 Jan. 14 at 10:32 PM

$ATRA What would be the best case scenario if the type A meeting is not successful? Pierre Fabre will perform a buy under for five dollars with a potential CVR for another 4 dollars if the drug gets approved and sales targets are met. In any case 9 dollars max? Is there hope waiting this out

2 · Reply

fantastex Jan. 14 at 6:14 PM

$ATRA uncertainty candle. Will it go lower with an offering soon? Expecting 3.50 to hit soon.

1 · Reply

DogBiscuit Jan. 14 at 6:06 PM

$ATRA looking for a comeback from an ugly event. Dog smelling fresh meats to begin cooking again longggg.RRrrrrr

0 · Reply

Jacklin123 Jan. 14 at 4:19 PM

$ATRA adding some more

2 · Reply

TezBunny Jan. 14 at 3:28 PM

$ATRA dump it

0 · Reply

Rachs88 Jan. 14 at 2:50 PM

$ATRA got in at 4.38 and will be out soon, good 10-20% return

0 · Reply

Market Cap	37.64M
Revenue (ttm)	128.94M
Net Income (ttm)	-85.40M
EPS (ttm)	N/A
PE Ratio	2.29
Forward PE	5.75
Profit Margin	-66.23%
Debt to Equity Ratio	0.00

Volume	292,800
Avg Vol	324,572
Day's Range	N/A - N/A
Shares Out	7.21M
Stochastic %K	62%
Beta	-0.41
Analysts	Sell
Price Target	$13.33